Serum biomarker panels for the diagnosis of gastric adenocarcinoma

HS Ahn¹, YS Shin², PJ Park², KN Kang², Y Kim³, H-J Lee⁴, H-K Yang⁵* and CW Kim⁵

¹Department of Surgery, Seoul National University-Boramae Hospital, Seoul, Korea; ²BioInfra Inc., Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea; ³Department of Statistics, Seoul National University College of Natural Sciences, Seoul, Korea; ⁴Department of Surgery and Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea; ⁵Department of Pathology, Cancer Research Institute, and Tumor Immunity Medical Research Center, Seoul National University College of Medicine, Seoul, Korea

BACKGROUND: Currently, serum biomarkers, which are sufficiently sensitive and specific for early detection and risk classification of gastric adenocarcinoma do not exist. Therefore, this study identified a panel of serum biomarkers for the diagnosis of gastric adenocarcinoma.

METHODS: A 29-plex array platform with 29 biomarkers, consisting of 11 proteins discovered through proteomics and 18 previously known to be cancer-associated, was constructed. A test/training set consisting of 120 gastric adenocarcinoma and 120 control samples were examined. After 13 proteins were selected as candidate biomarkers, multivariate classification analyses were used to identify algorithms for diagnostic biomarker combinations. These algorithms were independently validated using a set of 95 gastric adenocarcinoma and 51 control samples.

RESULTS: Epidermal growth factor receptor (EGFR), pro-apopliprotein Al (proApoAl), apolipoprotein A1, transthyretin (TTR), regulated upon activation, normally T-expressed and presumably secreted (RANTES), D-dimer, vitronectin (VN), interleukin-6, α-2 macroglobulin, C-reactive protein and plasminogen activator inhibitor-1 were selected as classifiers in the two algorithms. These algorithms differentiated between the majority of gastric adenocarcinoma and control serum samples in the training/test set with high accuracy (> 88%). These algorithms also accurately classified in the validation set (> 85%).

CONCLUSION: Two panels of combinatorial biomarkers, including EGFR, TTR, RANTES, and VN, are developed, which are less invasive method for the diagnosis of gastric adenocarcinoma. They could supplement clinical gastroscopic evaluation of symptomatic patients to enhance diagnostic accuracy.

British Journal of Cancer (2012) 106, 733–739. doi:10.1038/bjc.2011.592 www.bjcancer.com

© 2012 Cancer Research UK

Keywords: biomarker; gastric adenocarcinoma; diagnosis; screening

Gastric adenocarcinoma is the most common malignancy in Korea, and was the second leading cause of death by malignancy (19.4%) in 2001 (Lee et al, 2002; Ministry of Health and Welfare, 2003). Worldwide, it is the fourth most common cancer and the second most common cause of cancer-related deaths (700 000 deaths per year) following lung cancer (1.18 million deaths per year) (Parkin et al, 2005). Survival rates for gastric cancer patients are considerably lower than that of other common cancers, except for cancers of the liver, pancreas, and oesophagus. Five-year survival rates of patients with localised disease (61%) decreases to 25% after the cancer spreads to regional lymph nodes, and to 4% following distant metastasis (Jemal et al, 2008). Patients with symptomatic gastric cancer typically have more advanced lesions and shorter survival rates than asymptomatic patients (Kong et al, 2004). Early detection and proper treatment following precise risk classification are crucial for improving the outcome of gastric adenocarcinoma. Gastroscopic examination is the most reliable method for diagnosis of gastric adenocarcinoma. The high incidence of gastric adenocarcinoma led to the broad practice of gastroscopy in Korea and Japan. However, the low incidence in most countries resulted in positive predictive values of only 0.4–0.7 for this invasive approach. Therefore, the feasibility and effectiveness of gastroscopy is questionable for these countries (Maniotis et al, 1997; Bustamante et al, 2002; Genta, 2004).

Biomarkers that identify patients at high risk for gastric adenocarcinoma would increase the predictive value of endoscopy and have clinical benefits for detecting gastric adenocarcinoma. Therefore, extensive research has revealed several serum biomarkers for gastric cancer, including carcinoembryonic antigen (Reiter et al, 1997; Marrelli et al, 1999, 2001; Gaspar et al, 2001; Ishigami et al, 2001), cancer antigen 19-9 (Reiter et al, 1997; Marrelli et al, 1999, 2001; Gaspar et al, 2001; Ishigami et al, 2001), cancer antigen 72-4 (Kodama et al, 1995; Reiter et al, 1997; Marrelli et al, 1999, 2001; Gaspar et al, 2001; Ishigami et al, 2001), E-cadherin (Juhasz et al, 2003), pepsinogen (Miki et al, 2003), cytokines, and cytokeratin fragments (Wu et al, 1996; Nakata et al, 1998; Forones et al, 2001; Ikeguchi et al, 2009; Kim et al, 2009b). However, the sensitivity of the previously identified serum biomarkers was not
sufficient for diagnosis of gastric adenocarcinoma because the sensitivity of tumour markers such as carcinoembryonic antigen, cancer antigen 19-9, and CA72-4 was low (20–30%) (Kodama et al., 1995; Reiter et al., 1997; Marrelli et al., 1999, 2001; Gaspar et al., 2001; Ishigami et al., 2001).

In this study, we developed diagnostic biomarker panel algorithms and validated their performance differentiating patients with gastric adenocarcinoma from controls.

PATIENTS AND METHODS

Patient samples

Serum samples were collected from patients with newly diagnosed primary gastric adenocarcinoma without the presence of other cancers at Seoul National University Hospital. Ninety-two serum samples were obtained between November 2002 and December 2003 (period 1), and 123 serum samples were obtained between July 2006 and August 2007 (period 2). Control samples were collected from attendees of the cancer-screening programme of the Seoul National University Healthcare System between January and December 2004. All participants underwent (1) history taking, (2) physical examination, (3) routine blood and H. pylori IgG tests, (4) chest X-ray, (5) abdominal sonography or computed tomography, (6) esophagogastroduodenoscopy, (7) colonoscopy, sigmoidoscopy with stool haemoglobin, or computed tomographic tomography, (8) esophagogastroduodenoscopy, (7) colonoscopy, sigmoidoscopy with stool haemoglobin, or computed tomographic tomography, (8) mammography or breast sonography in women and/or thyroid sonography. Controls with confirmed cancer, suspected cancer, or inflammatory conditions that needed medical management were excluded, resulting in 171 control samples. In the early morning before medical treatment or surgery (74 from period 1 and 55 from period 2) and 51 control serum samples were grouped as the independent validation set (set 2). Patient demographics and clinical profiles are presented in Table 1.

Construction of 29-plex array platform and biomarker assay

For profiling gastric cancer-specific signatures using small samples, an antibody-based bead array method was used. Antibody-based microarray is one of the data-driven approaches, which bypass the identification step for individual markers, making this a faster and more direct method for profiling protein expression and translating this information (Kim et al., 2009a). And the xMAP bead-based technology (Luminex Corp., Austin, TX, USA) permits simultaneous analysis of numerous analytes in a single sample. This was successfully applied to identify serum profiles predicting responses to neoadjuvant chemotherapy in locally advanced breast cancer (Nolen et al., 2008). Recently, the characteristic serum profiles associated with breast cancer was reported using an antibody-based bead array platform (Kim et al., 2009a). For this study, a 29-plex array platform was constructed through an extensive screening process, using a serum bank that had 4500 samples from patients with cancers of the breast, colon, stomach, liver, and lung, as previously described (Kim et al., 2009a).

From the same serum bank, haptoglobin $a$, transthyretin (TTR),

Clinicopathological data on demographics and tumour characteristics (stage and size) were available for each patient whose serum was used for this study. Patients were divided into four groups on the basis of age (< 49, 50–59, 60–69, and >70-year-old). The T status, N status, and TNM stage of each tumour were classified according to the 6th edition of the AJCC classification (Sobin and Wittekind, 2002). Tumour sizes were divided into two groups ($\leq$2 and $>2$ cm) according to the size limit for endoscopic submucosal dissection (Goto da, 2007).

Serum samples from 120 patients with gastric adenocarcinoma (52 from period 1 and 68 from period 2) and 120 control serum samples were grouped as a training/test set (set 1) for the identification of the diagnostic panels. Serum samples from 95 patients with gastric adenocarcinoma (40 from period 1 and 55 from period 2) and 51 control serum samples were grouped as the independent validation set (set 2). Patient demographics and clinical profiles are presented in Table 1.

Table 1 Patient’s demographics and clinical profiles

| Training/test set (set1) | Validation set (set2) |
|-------------------------|----------------------|
| **Gastric adenocarcinoma** | **Control** | **Gastric adenocarcinoma** | **Control** |
| (n = 120) | (n = 120) | (n = 95) | (n = 51) |
| Age, years | 60.8 ± 10.4 | 52.0 ± 6.0 | 59.4 ± 11.1 | 52.1 ± 6.6 |
| Sex | | | | |
| Male | 75 | 66 | 59 | 28 |
| Female | 45 | 54 | 36 | 23 |
| Period of sample | | | | |
| Period 1 (Nov. 2002 – Dec. 2003) | 52 | 40 | 55 | |
| Period 2 (Jul. 2006 – Aug. 2007) | 68 | | | |
| Stage | | | | |
| I | 69 | 59 | | |
| II | 25 | 16 | | |
| III | 17 | 12 | | |
| IV | 9 | 8 | | |
| Endoscopic findings | | | | |
| No abnormality | 19 | 8 | | |
| Gastritis or ulcer | 98 | 40 | 40 | 40 |
| Hyperplastic/fundic polyp | 1 | 3 | | |
| Others | 2 | 0 | | |
Apolipoprotein A4, and Pro-apolipoprotein A1 (proApoA1) were identified through 2D-PAGE. β2-microglobulin, α-1-antitrypin, C-reactive protein, haemoglobin, apolipoprotein A2, apolipoprotein C3, and vitamin D-binding protein were identified through SELDI-TOF MS. On the basis of searching journals, another 18 serum proteins known to be cancer-associated were selected. Sandwich enzyme-linked immunosorbent assays for individual markers were used for validation, resulting in 29 candidates markers (Table 2). This 29-plex array platform was consisted of 4 multiplex kits and 18 simplex kits. A total of 16 markers were classified as four groups according to dilution factor and absence of cross reactivity, and were analysed through four multiplex kit.

The remaining 18 markers were analysed through individual simplex kits. Multiplex assays were performed using the xMAP bead-based technology (Luminex). Simplex assays were conducted using a conventional ELISA method, commercially available ELISA kits according to manufacturers’ instructions, a fully automated system for plasma protein determinations (BN II System; Siemens Healthcare Diagnostics, Marburg, Germany), or a bead array method. Bead array kits or antibodies for the construction of the 29-plex panel were purchased as listed in Table 2. Using the platform, the assays for each marker in set 1 were conducted simultaneously, and those in the set 2 were conducted simultaneously.

### Table 2  List of 29 markers

| Biomarkers         | Antigen                  | Primary antibody               | Secondary antibody           | Kit                                      |
|--------------------|--------------------------|-------------------------------|------------------------------|-----------------------------------------|
| Oncofetal protein  |                          |                               |                              |                                         |
| AFP                |                          |                               |                              | Rules-based medicine (Austin, TX, USA)  |
| CA 125*            |                          |                               |                              | Rules-based medicine                   |
| CA 19-9*           |                          |                               |                              | Rules-based medicine                   |
| CEA*               |                          |                               |                              | Rules-based medicine                   |
| PSA*               |                          |                               |                              | Rules-based medicine                   |
| PSA                |                          |                               |                              | Rules-based medicine                   |
| Tumour suppressor protein |              |                               |                              | R&D Systems (Minneapolis, MN, USA)     |
| DKK.3*             |                          |                               |                              |                                         |
| Cytokine/chemokine |                          |                               |                              |                                         |
| IL-6*              |                          |                               |                              | Milipore (St Charles, MO, USA)         |
| RANTES*            |                          |                               |                              | Milipore                                |
| Immune/Inflammation|                          |                               |                              |                                         |
| β2M*               |                          |                               |                              | Siemens Healthcare Diagnostics (Marburg, Germany) |
| Factor/hormone     |                          |                               |                              |                                         |
| EGFR*              |                          |                               |                              | R&D Systems                             |
| Acute phase protein|                          |                               |                              |                                         |
| A1AT*              |                          | Sigma-Aldrich (St Louis, MD, USA) | Acros Antibodies (Hidenhauen, Germany) | Biodesign International (Sacramento, CA, USA) |
| A2M*               |                          | EMD Chemicals Inc. (San Diego, CA, USA) | R&D Systems | Affinity Bioreagents, Inc. (Golden, CO, USA) |
| CRP*               |                          | Abcam (Cambridge, UK)         | Biodesign International      | Biodesign International                 |
| DD*                |                          |                               |                              | Siemens Healthcare Diagnostics         |
| HP*                |                          | Sigma-Aldrich (St Louis, MD, USA) | Biodesign International      | Siemens Healthcare Diagnostics         |
| Coagulation/thrombosis|                      | EMD Chemicals Inc. (San Diego, CA, USA) | Abcam                      | Siemens Healthcare Diagnostics         |
| Hgb*               |                          |                               |                              | Siemens Healthcare Diagnostics         |
| PAI-1*             |                          | Sigmacare (Seoul, Korea)      |                               | Siemens Healthcare Diagnostics         |
| Metabolism         |                          |                               |                              |                                         |
| ApoA1*             |                          | Bioinfra (Seoul, Korea)       |                              | Siemens Healthcare Diagnostics         |
| ApoA2*             |                          | Bioinfra (Seoul, Korea)       |                              | Milipore                                |
| ApoA4*             |                          | Bioinfra (Seoul, Korea)       |                              | Milipore                                |
| ApoC2*             |                          | Bioinfra (Seoul, Korea)       |                              | Milipore                                |
| proApoA1*          |                          | Bioinfra (Seoul, Korea)       |                              | Milipore                                |
| Adhesion           |                          |                               |                              |                                         |
| sICAM-1*           |                          |                               |                              | Milipore                                |
| sVCAM-1*           |                          |                               |                              | Milipore                                |
| VN*                |                          |                               |                              | Milipore                                |
| Others             |                          |                               |                              |                                         |
| VDBP*              |                          |                               |                              | Milipore                                |

Abbreviations: AFP = α-fetoprotein; Apo = apolipoprotein; A1AT = α-1-antitrypin; A2M = α-2-macroglubulin; β2M = β2-microglobulin; CA = cancer antigen; CEA = carcinoembryonic antigen; CRP = C-reactive protein; DD = D-dimer; DKK-3 = Dickkopf 3; EGFR = epidermal growth factor receptor; fPSA = free prostate-specific antigen; Hgb = haemoglobin; HP = Haptoglobin; IL = interleukin; PAI-1 = plasminogen activator inhibitor-1; proApo = pro-apolipoprotein; PSA = prostate-specific antigen; RANTES = regulated upon activation, normally T-expressed and presumably secreted; sICAM = soluble intercellular cell adhesion molecule-1; sVCAM = soluble vascular cell adhesion molecule-1; TTR = transthyretin; VDBP = vitamin D-binding protein; VN = vitronectin. *Twenty three markers were selected through literature search. β Twenty seven markers were discovered through surface-enhanced laser desorption/ionization time-of-flight (SELDI-TOF) mass spectrometry. A1AT, β2M, Hgb, and VDBP were identified from the peaks, which were differently represented in especially gastric adenocarcinoma serum compared with control serum. Four markers were discovered through two-dimensional polyacrylamide gel electrophoresis (2D-PAGE) using the serum of patients with gastric adenocarcinoma.
Data analysis

For identification of diagnostic algorithms based on the biomarker panel, two ratios of markers (ApoA1/proApoA1 and fPSA/tPSA) were additionally analysed. Prior to multivariate classification analyses, values were transformed into log value. Initially, the differences of serum biomarkers between two periods and between control group with normal and abnormal endoscopic findings were analysed. A receiver operating characteristic curve was constructed, and the area under the curve was calculated. As 29 markers were too many for one algorithm, the feature selection process, which reduced biomarkers included in one algorithm, was performed using random forests (RF). The average importance set at 100 was calculated using RF in set 1 (Breiman, 2001). A total of 13 ranked markers were selected for multivariate classification analysis.

For identification of algorithms distinguishing controls from patients with gastric carcinoma, two classification analysis methods, RF and support vector machine (SVM), were used. Random forest, proposed by Berinman, is a combination of tree predictors such that each tree depends on the values of a random vector sampled independently and with the same distribution for all trees in the forest (Breiman, 2001), and the idea behind SVMs is construction of a separating hyperplane or set of hyperplanes in a high or infinite dimensional space for classification (Vapnik, 1995; Furey et al, 2000; Dossat et al, 2007). This separating hyperplane is optimal in the sense of being a maximal distance to the nearest training data points of any class. Among the 240 samples in set 1, 70 samples from patients with gastric adenocarcinoma and 70 control samples were randomly assigned to training sets. The remaining 50 samples were assigned to test sets. RF and SVM were used with the training set to classify individuals as patients with gastric adenocarcinoma or controls. After training, each classification algorithm with different sets of classifiers was cross-validated with the test set. The prediction performances with accuracy (number of patients or controls identical to the result of the classification/examined total number), sensitivity (number of patients classified as patient with gastric adenocarcinoma/number of patients with gastric adenocarcinoma who were examined), and specificity (number of controls classified as control/number of controls who were examined) obtained from 50 randomly partitioned data sets were analysed. Four classification algorithms with selected biomarkers obtained from the experiment with set 1 were tested, without knowledge of true diagnosis, on an independent validation set (set 2). An ROC curve was constructed and the area under the curve was calculated. A P-value of <0.05 was considered statistically significant. The R program package (The R project of statistical computing, Wirtschaftsuniversität, Wien, Austria) was used for classification analysis to develop the algorithms.

### Table 3 Biomarker selection in set 1

| Marker | Avg.Imp | Rank | P-value |
|--------|---------|------|---------|
| EGFR   | 30.13   | 1    | 0.000   |
| ApoA1/proApoA1 | 29.70 | 2    | 0.000   |
| TTR    | 29.17   | 3    | 0.000   |
| proApoA1 | 26.89 | 4    | 0.000   |
| RANTES | 26.78   | 5    | 0.000   |
| ApoA1  | 25.35   | 6    | 0.000   |
| ApoA2  | 24.60   | 7    | 0.000   |
| DD     | 24.03   | 8    | 0.000   |
| VN     | 23.61   | 9    | 0.000   |
| IL-6   | 18.71   | 10   | 0.000   |
| CRP    | 18.47   | 11   | 0.000   |
| A2M    | 17.25   | 12   | 0.000   |
| PAI-1  | 16.80   | 13   | 0.000   |
| ApoC3  | 16.31   | 14   | 0.000   |
| ApoC2  | 15.24   | 15   | 0.000   |
| fPSA   | 14.08   | 16   | 0.118   |
| VDBP   | 13.24   | 17   | 0.000   |
| AP      | 12.98   | 18   | 0.004   |
| Hp     | 11.73   | 19   | 0.043   |
| sVCAM-1| 11.37   | 20   | 0.000   |
| Dkk3   | 10.94   | 21   | 0.000   |
| ApoA4  | 9.45    | 22   | 0.309   |
| CA19-9 | 9.13    | 23   | 0.525   |
| AIAT   | 8.99    | 24   | 0.349   |
| Hemo   | 8.96    | 25   | 0.663   |
| PSA    | 8.24    | 26   | 0.404   |
| sCAM   | 7.77    | 27   | 0.702   |
| fPSA/pfPSA | 7.16 | 28   | 0.875   |
| CA125  | 6.84    | 29   | 0.401   |
| CEA    | 6.29    | 30   | 0.877   |
| B2M    | 5.79    | 31   | 0.962   |

**Abbreviations:** AFP = α-fetoprotein; Apo = apolipoprotein; AIAT = α-1-antitrypsin; A2M = α-2-macroglobulin; β = β2-microglobulin; CA = cancer antigen; CEA = carcinoembryonic antigen; CRP = C-reactive protein; DD = D-dimer; Dkk3 = Dickkopf 3; EGFR = epidermal growth factor receptor; fPSA = free prostate-specific antigen; Hp = Haptoglobin α; IL = interleukin; PAI-1 = plasminogen activator inhibitor-1; proApo = pro-apolipoprotein; PSA = prostate-specific antigen; RANTES = regulated upon activation, normally T-expressed and presumably secreted; sCAM = soluble intercellular cell adhesion molecule-1; sVCAM = soluble vascular cell adhesion molecule-1; tPSA = total prostate-specific antigen; TTR = transthyretin; VDBP = vitamin D-binding protein; VN = vitronectin.

### RESULTS

There were no different levels of biomarkers between two periods and between controls with normal or abnormal endoscopic findings (data not shown). Via RF on set 1, 13 markers as Table 3 were selected for multivariate classification analysis. To identify biomarkers that distinguished sera from patients with gastric adenocarcinoma from control sera, multivariate classification analysis was performed with RF and SVM algorithms. The training set consisted of 70 serum samples from gastric adenocarcinoma patients and 70 control samples from set 1. After training, each algorithm with a different biomarker panel was cross-validated on the test set, to which the remaining 50 samples were assigned. The accuracy and classification error for two algorithms were calculated for each training and test set.

The classification algorithms with the top five ranked average accuracies are summarised in Table 4. The RT and SVM algorithms with the highest average accuracies distinguished between gastric adenocarcinoma and controls, with mean accuracies of 88.3% and 89.7%, respectively. These two algorithms were further tested on a separate, independent blinded set of 95 gastric adenocarcinoma sera and 51 control sera. The mean accuracies of the algorithms determined by RF and SVM were 89.2% and 85.6%, respectively. These accuracies were similar to those from set 1. Among the two algorithms, the biomarker panel from the RF algorithm containing 11 markers showed a higher accuracy in the validation set, though the area under the curve values of two algorithms were similar (Figure 1).

When analysing the diagnostic sensitivity according to TNM stage and tumour size, the sensitivity of the algorithms did not vary much from the overall sensitivity. However, the sensitivity for detecting the early-stage disease was slightly lower than that for advanced disease. Likewise, the sensitivity for tumours with sizes of ≤2 cm was slightly lower than that for tumours of >2 cm (Table 5). RF algorithms generally outperformed the SVM algorithms, regardless of TNM stage or tumour size. Additionally, SVM algorithms showed a higher sensitivity for small tumours.

### DISCUSSION

Although gastroscopy is the most reliable diagnostic method for detecting gastric adenocarcinoma, it is less accurate at detecting
Marker combination

**RF classification analysis**
- EGFR, TTR, proApoA1, RANTES, ApoA1, DD, VN, IL-6, CRP, A2M, PAI-1
- EGFR, TTR, proApoA1, RANTES, ApoA1, DD, VN, IL-6, A2M, PAI-1
- EGFR, TTR, proApoA1, RANTES, ApoA1, DD, VN, IL-6, CRP, A2M, PAI-1
- EGFR, proApoA1, TTR, proApoA1, RANTES, DD, VN, IL-6, CRP, A2M, PAI-1
- EGFR, proApoA1, TTR, proApoA1, RANTES, ApoA1, DD, VN, IL-6, CRP, A2M, PAI-1
- EGFR, proApoA1, TTR, proApoA1, RANTES, ApoA1, DD, VN, IL-6, CRP, A2M, PAI-1

**SVM classification analysis**
- EGFR, proApoA1, proApoA1, TTR, RANTES, DD, VN, IL-6, A2M
- EGFR, proApoA1, proApoA1, TTR, RANTES, ApoA1, DD, VN, IL-6, A2M
- EGFR, proApoA1, proApoA1, TTR, RANTES, ApoA1, DD, VN, IL-6, CRP, A2M, PAI-1
- EGFR, proApoA1, proApoA1, TTR, RANTES, ApoA1, DD, VN, IL-6, CRP, A2M, PAI-1
- EGFR, proApoA1, proApoA1, TTR, RANTES, ApoA1, DD, VN, IL-6, CRP, A2M, PAI-1
- EGFR, proApoA1, proApoA1, TTR, RANTES, ApoA1, DD, VN, IL-6, CRP, A2M, PAI-1

**Table 4** Diagnostic performance of classification algorithms with biomarker panel

| Marker combination | Training/test set (set1) | Validation set (set2) |
|--------------------|--------------------------|-----------------------|
| | Number of markers | Accuracy (%) | Sensitivity (%) | Specificity (%) | Accuracy (%) | Sensitivity (%) | Specificity (%) |
| **RF classification analysis** | | | | | | | |
| EGFR, TTR, proApoA1, RANTES, ApoA1, DD, VN, IL-6, CRP, A2M, PAI-1 | 11 | 88.3 | 90.1 | 86.4 | 89.2 | 88.8 | 89.7 |
| EGFR, TTR, proApoA1, RANTES, ApoA1, DD, VN, IL-6, A2M, PAI-1 | 10 | 89.0 | 89.3 | 86.7 | | | |
| EGFR, TTR, proApoA1, RANTES, ApoA1, DD, VN, IL-6, CRP, A2M, PAI-1 | 10 | 87.9 | 89.2 | 86.6 | | | |
| EGFR, proApoA1, TTR, proApoA1, RANTES, DD, VN, IL-6, CRP, A2M, PAI-1 | 11 | 87.9 | 89.1 | 86.7 | | | |
| EGFR, proApoA1, TTR, proApoA1, RANTES, ApoA1, DD, VN, IL-6, CRP, A2M, PAI-1 | 12 | 87.8 | 89.2 | 86.4 | | | |
| **SVM classification analysis** | | | | | | | |
| EGFR, proApoA1, proApoA1, TTR, RANTES, DD, VN, IL-6, A2M | 8 | 89.7 | 91.8 | 87.7 | 85.6 | 89.7 | 81.6 |
| EGFR, proApoA1, proApoA1, TTR, RANTES, ApoA1, DD, VN, IL-6, A2M | 9 | 89.2 | 91.2 | 87.2 | | | |
| EGFR, proApoA1, proApoA1, TTR, RANTES, ApoA1, DD, VN, IL-6, CRP, A2M, PAI-1 | 10 | 89.1 | 90.8 | 87.5 | | | |
| EGFR, proApoA1, proApoA1, TTR, RANTES, ApoA1, DD, VN, IL-6, CRP, A2M, PAI-1 | 11 | 89.1 | 91.1 | 87.1 | | | |
| EGFR, proApoA1, proApoA1, TTR, RANTES, ApoA1, DD, VN, IL-6, CRP, A2M, PAI-1 | 9 | 89.1 | 90.6 | 87.5 | | | |

Abbreviations: Apo = apolipoprotein; A2M = α-2 macroglobulin; CRP = C-reactive protein; DD = D-dimer; EGFR = epidermal growth factor receptor; IL = interleukin; PAI-1 = plasminogen activator inhibitor-1; proApo = pro-apolipoprotein; RANTES = regulated upon activation, normally T-expressed and presumably secreted; TTR = transthyretin; VN = vitronectin.

benign gastric diseases, such as peptic ulcers, especially in areas with low-to-intermediate rates of gastric cancer. The average percentage of missed diagnoses by endoscopy was reported to be 0.46–14%, but as high as 33%, depending on the country (Bramble et al, 2000; Amin et al, 2002; Yalamarthi et al, 2004; Voutilainen and Juhola, 2005; Raftopoulos et al, 2010). This variation might have been caused by inter-observer variation, suboptimal correlations with histopathology, unimpaired visualization of all anatomic sub-regions, such as remnant stomach after surgery, and delays in receiving endoscopy after anti-secretory medications (Bramble et al, 2000; Voutilainen and Juhola, 2005). Moreover, possible discomfort and anxiety of patients who underwent endoscopy led to prevalent use of conscious sedation, which caused adverse outcomes of gastroscopy with an incidence of 0.54% and fatalities of 0.03% (Froehlich et al, 1995; Abraham et al, 2002).

To overcome these limitations and invasiveness of gastroscopy, we developed a novel panel of biomarkers that differentiate between patients with gastric adenocarcinoma and healthy controls. During development, cancer cells secrete proteins required for tumour growth within the microenvironment of the incipient tumour. Additionally, cancer systemically mounts an immunological defense, which consists of innate and adaptive responses, including autoantibody production and migration of inflammatory cells such as macrophages, histiocytes, and lymphocytes into the tumour (Ohno et al, 2003; Patz et al, 2007; Yuan et al, 2008). As gastric adenocarcinoma is considered to have heterogeneous phenotypes, we predicted that a combination of tumour-expressed and host-response proteins would yield candidate biomarkers.

Two algorithms determined by RF, and SVM analysis differentiated between serum samples from gastric adenocarcinoma patients and control serum in the training/test set with high accuracy (>88%). These algorithms also accurately classified in the validation set (>85%). The sensitivity for accurately diagnosing advanced-stage and large tumours was slightly better than that for diagnosing early-stage and small tumours. However, the overall sensitivity was sustained regardless of TNM stage and tumour size. Although none of the individual markers showed sufficient diagnostic power independently, the biomarker panel identified in this study performed well. The RF algorithm containing 11 biomarkers outperformed the other algorithms, regardless of TNM stage or tumour size. However, the SVM algorithm performed well for diagnosing small tumours.
Several reports have successfully profiled serum proteins for the diagnosis of gastric cancer (Liang et al, 2006; Ren et al, 2006; Lim et al, 2007). These studies emphasised the feasibility of proteomics methodologies rather than biomarkers, and adopted only three to four markers as classifiers after profiling was performed on a small number of cases. In this study, identification of candidate markers was based on analysis of a serum bank consisting of 4500 serum samples and previously published literature. The development and validation of these biomarker panel algorithms was performed using a considerable number of cases.

The diagnostic biomarker panel algorithms in this study have some weaknesses. First, the number of classifiers in these biomarker panels was higher than other previously reported panels (Patz et al, 2007; Ueland et al, 2010; Yurkowsky et al, 2010). Two algorithms included more than eight classifiers. Possibly, gastric cancer does not have concrete biomarkers that can distinguish cancer from control serum samples as do breast and ovarian cancers. Additional biomarkers might enhance the diagnostic accuracy; however, more markers mean increased cost and time requirements. Second, except for DD and C-reactive protein, the levels of all algorithm-selected biomarkers were significantly lower in patients with gastric adenocarcinoma than in the controls (data not shown). It is more difficult and less accurate to assay low levels of biomarkers than high levels. The accuracy of the assay for measuring decreased biomarker levels can be related to the method of analysis and the skill of the technician. Therefore, simple and cheap methods for analysis of the biomarkers, such as multiplex-bead arrays, are needed. Third, important biomarkers might not have been identified as classifiers because early-stage tumours were included much more often than were advanced-stage tumours in this study.

CONCLUSIONS

Two diagnostic biomarker panel algorithms that included eight to eleven biomarkers, including epidermal growth factor receptor (EGFR), TTR, ApoA1/proApoA1, proApoA1, RANTES, ApoA1, DD, vitronectin, IL-6, C-reactive protein, A2M, and PAI-1, were developed and validated. Among the diagnostic algorithms, the RF algorithm with more classifiers than the others, in general, outperformed the others regardless of TNM stage or tumour size. The SVM algorithm performed well for the diagnosis of small tumours. These two less-invasive biomarker panels could supplement clinical gastrointestinal evaluation of symptomatic patients to enhance diagnostic accuracy. Further studies in more patients are required to refine the diagnostic algorithms with the expectation that an efficient, optimal diagnostic strategy will improve patient outcomes.

ACKNOWLEDGEMENTS

This research was supported by a Grant No. 10035535 of core source technology R & D project, Ministry of Knowledge Economy, Republic of Korea through the Tumor Immunity Medical Research Center and by a Grant No. 04-2006-0110 from SNUH research fund through the Department of Surgery at Seoul National University College of Medicine.

REFERENCES

Abraham N, Barkun A, Larocque M, Fallone C, Mayrand S, Baffis V, Cohen A, Daly D, Daoud H, Joseph L (2002) Predicting which patients can undergo upper endoscopy comfortably without conscious sedation. Gastrointest Endosc 56: 180–189
Amin A, Gilmour H, Graham L, Paterson-Brown S, Terrace J, Crofts TJ (2000) Gastric adenocarcinoma missed at endoscopy. J R Coll Surg Edinb 47: 681–684
Bramble MG, Suvakov Z, Hungin AP (2000) Detection of upper gastrointestinal cancer in patients taking antisecretory therapy prior to gastroscopy. Gut 46: 464–467
Breiman L (2001) Random forest. Machine Learning 45: 5–32
Bustamante M, Devesa F, Borghol A, Ortuno J, Ferrando MJ (2002) Accuracy of the initial endoscopic diagnosis in the discrimination of gastric ulcers: is endoscopic follow-up study always needed? J Clin Gastroenterol 35: 25–28
Dossat N, Mange A, Solassol J, Jacot W, Lhermitte L, Maudelonde T, Daures JP, Molinari N (2007) Comparison of supervised classification methods for protein profiling in cancer diagnosis. Cancer Inform 3: 295–305
Forones NM, Mandowsky SV, Lourenco LG (2001) Serum levels of interleukin-2 and tumor necrosis factor-alpha correlate to tumor progression in gastric cancer. Hepatogastroenterology 48: 1199–1201
Froehlich F, Schwizer W, Thorens J, Kohler M, Conyers JJ, Fried M (1995) Conscious sedation for gastroscopy: patient tolerance and cardiorespiratory parameters. Gastroenterology 108: 697–704
Furey TS, Cristianini N, Duffy N, Bednarški DW, Schummer M, Haussler D (2000) Support vector machine classification and validation of cancer tissue samples using microarray expression data. Bioinformatics 16: 906–914
Gaspar MJ, Arribas I, Coca MC, Diez-Alonso M (2001) Prognostic value of carcinoembryonic antigen, CA 19-9 and CA 72-4 in gastric carcinoma. Tumour Biol 22: 318–322
Genta RM (2004) Screening for gastric cancer: does it make sense? Aliment Pharmacol Ther 20(Suppl 2): 42–47
Gotoda T (2007) Endoscopic resection of early gastric cancer. Gastric Cancer 10: 1–11
Ikuguchi M, Hatada T, Yamamoto M, Miyake T, Matsunaga T, Fukumoto Y, Yamada Y, Fukuda K, Saito H, Tatebe S (2009) Serum interleukin-6 and -10 levels in patients with gastric cancer. Gastric Cancer 12: 95–100
Ishigami S, Natsugoe S, Hokita S, Che X, Tokuda K, Nakajo A, Iwashige H, Tokushige M, Watanabe T, Takao S, Aikou T (2001) Clinical importance of preoperative carcinoembryonic antigen and carbohydrate antigen 19-9 levels in gastric cancer. J Clin Gastroenterol 32: 41–44

**Table 5** Comparison of sensitivity according to size and TNM stage

| Algorithm | Set          | Sensitivity (%) according to size | Sensitivity (%) according to TNM stage |
|-----------|-------------|----------------------------------|----------------------------------------|
|           |             | ≤ 2 cm                           | > 2 cm                                 | Stage I–II | Stage III–IV |
| RF        | Training/test set | 87.0                             | 92.6                                   | 91.0       | 94.4         |
|           | Validation set | 81.8                             | 95.7                                   | 92.3       | 92.9         |
| SVM       | Training/test set | 91.3                             | 91.6                                   | 90.0       | 94.4         |
|           | Validation set | 72.7                             | 94.3                                   | 88.5       | 92.9         |

Abbreviations: RF = random forests; SVM = support vector machine.
Serum biomarker panels for gastric adenocarcinoma diagnosis

HS Ahn et al

Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ (2008) Cancer statistics, 2008. CA Cancer J Clin 58: 71 – 96
Juhasz M, Ebert MP, Schulz HU, Rocken C, Molnar B, Tulassay Z, Malfertheiner P (2003) Dual role of serum soluble E-cadherin as a biological marker of metastatic development in gastric cancer. Scand J Gastroenterol 38: 850 – 855
Kim BK, Lee JW, Park PJ, Shin YS, Lee WY, Lee KA, Ye S, Hyun H, Kang KN, Yeo D, Kim Y, Ohn SY, Noh DY, Kim CW (2009a) The multiplex bead array approach to identifying serum biomarkers associated with breast cancer. Breast Cancer Res 11: R22
Kim DK, Oh SY, Kwon HC, Lee S, Kwon KA, Kim BG, Kim SG, Kim SH, Jang JS, Kim MC, Kim KH, Han JY, Kim HJ (2009b) Clinical significances of preoperative serum interleukin-6 and C-reactive protein level in operable gastric cancer. BMC Cancer 9: 155
Kodama I, Koufuji K, Kawabata S, Tetsu S, Tsuji Y, Takeda J, Kakegawa T (1995) The clinical efficacy of CA 72-4 as serum marker for gastric cancer in comparison with CA19-9 and CEA. Int Surg 80: 45 – 48
Kong SH, Park DJ, Lee HJ, Jung HC, Lee KU, Choe KJ, Yang HK (2004) Clinicopathologic features of asymptomatic gastric adenocarcinoma patients in Korea. Jpn J Clin Oncol 34: 1 – 7
Lee HJ, Yang HK, Ahn YO (2002) Gastric cancer in Korea. Gastric Cancer 5: 177 – 182
Liang Y, Fang M, Li J, Liu CB, Rudd JA, Fang M, Li J, Liu CB, Rudd JA, Kung HF, Yew DT (2006) Serum soluble interleukin-2 receptor surface-enhanced laser desorption/ionization time-of-flight mass spectrometry. Int J Biol Markers 22: 281 – 286
Maniatis AG, Eisen GM, Brazer SR (1997) Endoscopic discrimination of gastric ulcers. J Clin Gastroenterol 24: 203 – 206
Marrelli D, Pinto E, De Stefano A, Farnetani M, Garosi L, Roviello F (1999) Prognostic value of preoperative serum levels of CEA, CA 19-9 and CA 72-4 in operable gastric carcinoma. Anticancer Res 19: 203 – 206
Pantel K, Zalcman G, Puisieux F, Couach J, Michon M, Aller J, Binz W, Eng F K, Chi CW (1996) Clinical utility of CA 19-9 and CA 72-4 in gastric carcinoma. Oncology 57: 55 – 62
Miki K, Morita M, Sasajima M, Hoshina R, Kanda E, Urita Y (2003) Usefulness of gastric cancer screening using the serum pepsinogen test method. Am J Gastroenterol 98: 735 – 739
Ministry of Health and Welfare (2003) Annual Report of the Korea Central Cancer Registry 2001
Nakata B, Chung KH, Kato Y, Yamashita Y, Inui A, Arimoto Y, Maeda K, Onoda N, Sawada T, Sowa M (1998) Serum soluble interleukin-2 receptor level as a prognostic indicator in gastric cancer. Br J Cancer 77: 1820 – 1824
Nelen BM, Marks JR, Ta’asan S, Rand A, Luong TM, Wang Y, Blackwell K, Lokshin AE (2008) Serum biomarker profiles and response to neoadjuvant chemotherapy for locally advanced breast cancer. Breast Cancer Res 10: R45
Ohno S, Inagawa H, Dhar DK, Fujii T, Ueda S, Tachibana M, Suzuki N, Inoue M, Soma G, Nagase N (2003) The degree of macrophage infiltration into the cancer cell nest is a significant predictor of survival in gastric cancer patients. Anticancer Res 23: 5015 – 5022
Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55: 74 – 108
Patz JR, Campa MJ, Gottlin EB, Kusmartseva I, Guan XR, Herndon II JE (2007) Panel of serum biomarkers for the diagnosis of lung cancer. J Clin Oncol 25: 5578 – 5583
Rafopoulos SC, Segarajasingam DS, Burke V, Ee HC, Yusoff IF (2010) A cohort study of missed and new cancers after esophagogastroduodenoscopy. Am J Gastroenterol 105: 1292 – 1297
Reiter W, Stieber P, Reuter C, Nagel D, Cramer C, Pahl H, Fath-Moghadam A (1997) Prognostic value of preoperative serum levels of CEA. J Clin Oncol 15: 2903 – 2906
Ren H, Du N, Liu G, Hu HT, Tian W, Deng ZP, Shi JS (2006) Analysis of variabilities of serum proteomic spectra in patients with gastric cancer before and after operation. World J Gastroenterol 12: 2789 – 2792
Robson LH, Wittekind CH (eds) (2002) TNM Classification of Malignant Tumors, 6th edn. Wiley-Liss: New York
The R project of statistical computing [http://www.rproject.org]
Ueland PR, Desimone CP, Leigh S, Ware RA, Goodrich S, Podzielski I, Smith A, Santosu JT, Negell J, Zhang Z (2010) The OVA1 test improves the preoperative assessment of ovarian tumors. Gynecol Oncol 116: 82 Vapnik V (1995) The Nature of Statistical Learning Theory. Springer-Verlag: New York
Voutilainen ME, Juhaula MT (2005) Evaluation of the diagnostic accuracy of gastroscopy to detect gastric tumours: clinicopathological features and prognosis of patients with gastric cancer missed on endoscopy. Eur J Gastroenterol Hepatol 17: 1345 – 1349
Wu CW, Wang SR, Chao MF, Wu TC, Lui WY, P Eng F K, Chi CW (1996) Serum interleukin-6 levels reflect disease status of gastric cancer. Am J Gastroenterol 91: 1417 – 1422
Yalamarthi S, Witherspoon P, McCole D, Auld CD (2004) Missed diagnoses in patients with upper gastrointestinal cancers. Endoscopy 36: 874 – 879
Yuan A, Chen JJ, Yang PC (2008) Pathophysiology of tumor-associated macrophages. Adv Clin Chem 45: 199 – 223
Yurkovetsky Z, Skates S, Lomakin A, Nolen B, Pulsipher T, Modugno F, Marks J, Godwin A, Gorelik E, Jacobs I, Menon U, Lu K, Badgwell D, Bast Jr RC, Lokshin AE (2010) Development of a multiparameter assay for early detection of ovarian cancer. J Clin Oncol 28: 2159 – 2166

This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License.